Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License ...
July 3 (Reuters) - Sanofi (SASY.PA), opens new tab and partner Regeneron (REGN.O), opens new tab on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a ...
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Sanofi logo at the company's headquarters during the annual results news conference in Paris (Reuters) -Sanofi won ...
Dupixent also met all secondary endpoints in both trials, including demonstrating a significant reduction in the need for systemic corticosteroids or surgery, and improvements in smell and chronic ...
Sanofi looks compelling with strong fundamentals and a robust pipeline. Click for this updated look at SNY stock and why I ...
Dupixent meets early efficacy threshold for continuation in ongoing Phase 3 trial of patients with COPD; second confirmatory trial will commence in third quarter of 2020 Regeneron Pharmaceuticals, Inc ...
May 20 (Reuters) - Sanofi (SASY.PA), opens new tab won expanded U.S. approval for its best-selling Dupixent injection to treat an allergic inflammation of the esophagus, the Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results